NPPB and neoplasm: To dive deeper into disease progression for rare NET related pathologies this registry would benefit from a more thorough observational follow-up on biomarkers (NT-proBNP, 5-HIAA and chromogranin A) and clinical data including tumor load and typical carcinoid associated symptoms (abdominal pain, flush and diarrhea).